VERTEX PHARMACEUTICALS INC / MA (VRTX) Operating Margin
- Operating margin · 12 months: Value 37.95%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 37.95% | Operating income / revenue. Period ending 2026-06-30. $4.78B ÷ $12.59B × 100 ≈ 37.95% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 4.78B USD | Operating Income (Loss) |
| Revenue | 12.59B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 1.76B USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 2.01B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4.78B | $12.59B | $1.76B | (m) | $2.01B | 37.95% |
| 2026-03-31 | $4.68B | $12.22B | $1.68B | (m) | $1.85B | 38.31% |
| 2025-12-31 | $4.17B | $12.00B | $1.65B | (m) | $1.75B | 34.77% |
| 2025-09-30 | $3.99B | $11.72B | $1.61B | (m) | $1.64B | 34.06% |
| 2025-06-30 | $3.92B | $11.42B | $1.59B | (m) | $1.57B | 34.36% |
| 2025-03-31 | $-742.30M | $11.10B | $1.55B | (m) | $1.52B | -6.69% |
| 2024-12-31 | $-232.90M | $11.02B | $1.53B | (m) | $1.46B | -2.11% |
| 2024-09-30 | $-270.40M | $10.63B | $1.48B | (m) | $1.46B | -2.54% |
| 2024-06-30 | $-348.60M | $10.34B | $1.40B | (m) | $1.35B | -3.37% |
| 2024-03-31 | $4.19B | $10.19B | $1.34B | (m) | $1.24B | 41.16% |
| 2023-12-31 | $3.83B | $9.87B | $1.26B | (m) | $1.14B | 38.83% |
| 2023-09-30 | $3.88B | $9.65B | $1.18B | (m) | $1.03B | 40.16% |
| 2023-06-30 | $3.97B | $9.51B | $1.15B | (m) | $1.02B | 41.72% |
| 2023-03-31 | $4.05B | $9.21B | $1.10B | (m) | $970.60M | 43.93% |
| 2022-12-31 | $4.31B | $8.93B | $1.08B | (m) | $944.70M | 48.23% |
| 2022-09-30 | $4.15B | $8.70B | $1.04B | (m) | $932.50M | 47.72% |
| 2022-06-30 | $4.08B | $8.35B | $991.50M | (m) | $883.90M | 48.85% |
| 2022-03-31 | $2.94B | $7.95B | $957.70M | $3.20B | $863.20M | 36.93% |
| 2021-12-31 | $2.78B | $7.57B | $904.20M | $3.05B | $840.10M | 36.73% |
| 2021-09-30 | $2.65B | $7.13B | $859.91M | $2.82B | $796.78M | 37.17% |
| 2021-06-30 | $2.27B | $6.68B | $809.58M | $2.82B | $783.14M | 33.93% |
| 2021-03-31 | $3.02B | $6.41B | $766.13M | $1.84B | $780.27M | 47.14% |
| 2020-12-31 | $2.86B | $6.21B | $736.30M | $1.83B | $770.46M | 46.03% |
| 2020-09-30 | $2.66B | $5.99B | $718.21M | $1.84B | $753.89M | 44.43% |
| 2020-06-30 | $2.09B | $5.40B | $663.94M | $1.91B | $729.01M | 38.67% |
| 2020-03-31 | $1.64B | $4.82B | $615.16M | $1.86B | $693.71M | 34.05% |
| 2019-12-31 | $1.20B | $4.16B | $547.76M | $1.75B | $658.50M | 28.77% |
| 2019-09-30 | $773.82M | $3.62B | $485.04M | $1.71B | $616.43M | 21.38% |
| 2019-06-30 | $880.14M | $3.45B | $464.38M | $1.49B | $594.05M | 25.48% |
| 2019-03-31 | $783.06M | $3.27B | $433.02M | $1.45B | $574.85M | 23.98% |
| 2018-12-31 | $635.15M | $3.05B | $409.54M | $1.42B | $557.62M | 20.84% |
| 2018-09-30 | $633.16M | $2.83B | (m) | $1.29B | $539.20M | 22.38% |
| 2018-06-30 | $101.47M | $2.62B | (m) | $1.41B | $522.62M | 3.87% |
| 2018-03-31 | $-18.70M | $2.41B | (m) | $1.36B | $512.56M | -0.77% |
| 2017-12-31 | $123.24M | $2.49B | (m) | $1.32B | $496.08M | 4.95% |
| 2017-09-30 | $37.15M | $2.30B | (m) | $1.27B | $471.19M | 1.62% |
| 2017-06-30 | $344.46M | $2.13B | (m) | $1.08B | $456.54M | 16.16% |
| 2017-03-31 | $295.11M | $2.02B | (m) | $1.07B | $440.94M | 14.62% |
| 2016-12-31 | $9.94M | $1.70B | (m) | $1.05B | $432.83M | 0.58% |
| 2016-09-30 | $-83.41M | $1.66B | (m) | $1.11B | $419.47M | -5.02% |
| 2016-06-30 | $-134.71M | $1.56B | (m) | $1.08B | $413.19M | -8.65% |
| 2016-03-31 | $-309.22M | $1.29B | (m) | $1.04B | $395.93M | -23.94% |
| 2015-12-31 | $-466.88M | $1.03B | (m) | $995.92M | $376.57M | -45.23% |
| 2015-09-30 | $-566.80M | $758.96M | (m) | $887.20M | $358.55M | -74.68% |
| 2015-06-30 | $-638.98M | $628.13M | (m) | $831.86M | $334.00M | -101.73% |
| 2015-03-31 | $-648.36M | $600.47M | (m) | $832.49M | $317.06M | -107.97% |
| 2014-12-31 | $-692.41M | $580.41M | (m) | $855.51M | $305.41M | -119.30% |
| 2014-09-30 | $-842.51M | $787.02M | (m) | $929.19M | $306.09M | -107.05% |
| 2014-06-30 | $-805.45M | $829.73M | (m) | $941.98M | $314.60M | -97.07% |
| 2014-03-31 | $-681.55M | $1.00B | (m) | $939.65M | $343.68M | -68.01% |
| 2013-12-31 | $-903.45M | $1.21B | (m) | $918.78M | $362.34M | -74.54% |
| 2013-09-30 | $-706.76M | $1.19B | (m) | $882.28M | $397.61M | -59.15% |
| 2013-06-30 | $-573.77M | $1.31B | (m) | $853.82M | $407.54M | -43.83% |
| 2013-03-31 | $-527.61M | $1.42B | (m) | $827.91M | $418.53M | -37.24% |
| 2012-12-31 | $2.33M | $1.53B | (m) | $806.18M | $436.80M | 0.15% |
| 2012-09-30 | $303.71M | $1.76B | (m) | $779.51M | $448.23M | 17.29% |
| 2012-06-30 | $520.49M | $2.08B | (m) | $768.40M | $461.19M | 25.03% |
| 2012-03-31 | $365.37M | $1.78B | (m) | $745.47M | $440.34M | 20.58% |
| 2011-12-31 | $113.82M | $1.41B | (m) | $707.71M | $400.72M | 8.07% |
| 2011-09-30 | $-276.72M | $912.81M | (m) | $690.16M | $341.32M | -30.31% |
| 2011-06-30 | $-692.01M | $277.40M | (m) | $671.54M | $279.52M | -249.46% |
| 2011-03-31 | $-695.69M | $194.60M | (m) | $653.02M | $223.77M | -357.49% |
| 2010-12-31 | $-696.08M | $143.37M | (m) | $637.42M | $187.80M | -485.51% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-614.01M | $101.89M | (m) | $550.27M | $130.19M | -602.63% |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $-462.71M | $175.50M | (m) | $516.91M | $101.29M | -263.65% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |